MX2014001920A - Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma. - Google Patents

Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma.

Info

Publication number
MX2014001920A
MX2014001920A MX2014001920A MX2014001920A MX2014001920A MX 2014001920 A MX2014001920 A MX 2014001920A MX 2014001920 A MX2014001920 A MX 2014001920A MX 2014001920 A MX2014001920 A MX 2014001920A MX 2014001920 A MX2014001920 A MX 2014001920A
Authority
MX
Mexico
Prior art keywords
apolipoprotein
fusion protein
lipid particle
particle containing
shortened tetranectin
Prior art date
Application number
MX2014001920A
Other languages
English (en)
Inventor
Roberto Falkenstein
Martin Bader
Christian Schantz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014001920A publication Critical patent/MX2014001920A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)

Abstract

Aquí se describe una proteína de fusión tetranectina-apolipoproteí na A-I acortada y una partícula lipídica que comprende la proteína de fusión tetranectina-apolipoproteína A-I acortada así como la utilización de las mismas.
MX2014001920A 2011-08-25 2012-08-22 Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma. MX2014001920A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11178746 2011-08-25
PCT/EP2012/066301 WO2013026860A1 (en) 2011-08-25 2012-08-22 Shortened tetranectin-apolipoprotein a-i fusion protein, a lipid particle containing it, and uses thereof

Publications (1)

Publication Number Publication Date
MX2014001920A true MX2014001920A (es) 2014-04-14

Family

ID=46704687

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001920A MX2014001920A (es) 2011-08-25 2012-08-22 Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma.

Country Status (11)

Country Link
US (2) US8791063B2 (es)
EP (1) EP2748191A1 (es)
JP (2) JP6207507B2 (es)
KR (1) KR20140054115A (es)
CN (1) CN103703023A (es)
AR (1) AR087640A1 (es)
BR (1) BR112013033562A2 (es)
CA (1) CA2838070A1 (es)
MX (1) MX2014001920A (es)
RU (1) RU2014108240A (es)
WO (1) WO2013026860A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11124558B2 (en) * 2017-06-02 2021-09-21 The Feinstein Institutes For Medical Research Use of tetranectin and peptide agonists to treat inflammatory diseases

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608347A (en) 1982-04-15 1986-08-26 Bernstam Victor A Compositions, uses and methods creating reverse micelles for the clarification of biological fluids to obtain undistorted assay of analytes following clarification
DE4192335C2 (de) 1990-09-18 1996-02-08 Biotech Australia Pty Ltd T-Zell-Epitope
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
AU736707B2 (en) 1997-06-11 2001-08-02 Anaphore, Inc. Trimerising module
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
EP0972838B1 (en) 1998-07-15 2004-09-15 Roche Diagnostics GmbH Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy
US6291245B1 (en) 1998-07-15 2001-09-18 Roche Diagnostics Gmbh Host-vector system
EP1276754A4 (en) 2000-04-14 2005-04-06 Nuvelo Inc Materials and methods relating to lipid metabolism
EP2343317A1 (en) * 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
ITMI20021058A1 (it) 2002-05-17 2003-11-17 Chiesi Farma Spa Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito
BR0310100A (pt) 2002-05-17 2007-04-27 Esperion Therapeutics Inc métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
AU2003239489A1 (en) 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
AU2003239777A1 (en) * 2002-07-05 2004-01-23 Borean Pharma A/S Multimerised growth hormone fusion proteins
CA2443365C (en) 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
US20040180445A1 (en) 2003-03-12 2004-09-16 Domanico Michael J. Methods and compositions for purification of nucleic acid from a host cell
DE60302776T2 (de) 2003-06-12 2006-08-17 F. Hoffmann-La Roche Ag Verfahren zur rekombinanten Herstellung von Polypeptiden
PE20050438A1 (es) 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
WO2005041886A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Methods for generating or increasing revenues related to pain inhibitor commerce
MXPA06007635A (es) 2003-12-30 2007-01-30 Wyeth Corp Formulaciones de proteinas hidrofobas en una composicion inmunogenica que tiene tolerabilidad mejorada.
US20060019870A1 (en) 2004-01-28 2006-01-26 O'donnell Francis E Jr Apoprotein cochleate compositions
US20090143276A1 (en) * 2007-10-08 2009-06-04 Anaphore, Inc. Trimeric IL-1Ra
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
JP2008514240A (ja) 2004-10-01 2008-05-08 インヴィトロジェン コーポレーション 生体分子のインビトロ合成用の供給バッファー、系、及び方法
WO2006047614A2 (en) 2004-10-26 2006-05-04 Invitrogen Corporation Compositions and methods for analyzing biomolecules using mass spectroscopy
US20060160721A1 (en) 2004-12-22 2006-07-20 Baylor College Of Medicine Method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
US8206750B2 (en) * 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
US20060275356A1 (en) 2005-05-25 2006-12-07 Burgess James W Pharmaceutical compositions for treating or preventing coronary artery disease
US20080248565A1 (en) 2007-03-01 2008-10-09 Invitrogen Corporation Isolated phospholipid-protein particles
US20070254832A1 (en) 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
CA2653840A1 (en) 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Use of a peptide/phospholipid complex acting as a reverse lipid transport agonist for treatment of valvular stenosis
WO2008013885A2 (en) 2006-07-25 2008-01-31 Stratagene California Zwitterionic detergents for the storage and use of dna polymerases
US9637753B2 (en) 2006-08-10 2017-05-02 Plantechno S.R.L. In-plant production of oligomeric (comprising three or more units) forms of human Apo A-1 protein muteins
WO2008094905A2 (en) 2007-01-29 2008-08-07 Lipid Sciences, Inc. Encapsulated hdl mimetic peptides
FR2915490B1 (fr) 2007-04-26 2011-10-28 Univ Joseph Fourier Grenoble I Formation de proteoliposomes contenant des proteines membranaires a l'aide d'un systeme de synthese proteique acellulaire
AU2008266753A1 (en) 2007-06-20 2008-12-24 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. ApoA-1 peptide mimetics
WO2009036460A2 (en) 2007-09-14 2009-03-19 Ambrx, Inc. Modified human apolipoprotein a-i polypeptides and their uses
WO2009048961A1 (en) * 2007-10-08 2009-04-16 Anaphore, Inc. Trimeric il-1ra
WO2009097587A2 (en) 2008-01-30 2009-08-06 The Rockefeller University Nanoscale bound bilayers, methods of use and production
CA2722183C (en) 2008-04-25 2018-09-18 Northwestern University Nanostructures suitable for sequestering cholesterol and other molecules
EP2305309A2 (en) * 2008-06-13 2011-04-06 Proyecto de Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
CA2788223A1 (en) 2009-01-23 2010-07-29 Institut De Cardiologie De Montreal Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex
WO2011043835A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
US20120190609A1 (en) 2010-08-30 2012-07-26 Martin Bader Method for producing a lipid particle, the lipid particle itself and its use
BR112013004396A2 (pt) 2010-08-30 2016-05-17 Hoffmann La Roche alimentação alcalina
EP2611921A2 (en) 2010-08-30 2013-07-10 F.Hoffmann-La Roche Ag Prokaryotic expression construct
MX2013002145A (es) 2010-08-30 2013-04-03 Hoffmann La Roche Tetranectina-apolipoproteina a-i, particulas lipidicas que la contienen y utilizacion de la misma.
CN103703015B (zh) 2011-08-25 2019-07-05 霍夫曼-拉罗奇有限公司 阳离子和阴离子交换层析法
CA2860735A1 (en) 2012-02-29 2013-09-06 F. Hoffmann-La Roche Ag Method for reduction of 1->2 reading frame shifts
JP2015508662A (ja) 2012-02-29 2015-03-23 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ １→３リーディングフレームシフトを減少させるための方法
HK1198445A1 (en) 2012-02-29 2015-04-24 霍夫曼-拉罗奇有限公司 On-column enzymatic cleavage

Also Published As

Publication number Publication date
CA2838070A1 (en) 2013-02-28
US20130231273A1 (en) 2013-09-05
US8791063B2 (en) 2014-07-29
WO2013026860A1 (en) 2013-02-28
BR112013033562A2 (pt) 2017-02-14
RU2014108240A (ru) 2015-09-27
JP6207507B2 (ja) 2017-10-04
JP2014529602A (ja) 2014-11-13
CN103703023A (zh) 2014-04-02
JP2017171670A (ja) 2017-09-28
US20150011459A1 (en) 2015-01-08
EP2748191A1 (en) 2014-07-02
US9139640B2 (en) 2015-09-22
KR20140054115A (ko) 2014-05-08
AR087640A1 (es) 2014-04-09

Similar Documents

Publication Publication Date Title
EP4223770A3 (en) Novel fusion molecules and uses thereof
MX2019003214A (es) Formulaciones de proteina de inmunoglobulina del dominio variable dual estable.
MY168166A (en) Polymer and Composition Including Same, and Adhesive Composition
EP2698386B8 (en) Fusion protein
WO2012078816A9 (en) Proteins that efficiently generate singlet oxygen
MY157836A (en) Laminate
KR20180085063A (ko) 신규 단백질 소재
CA141191S (en) Packaging
EP2521143B8 (de) Magnetisch wirksamer Werkstoff
CA141825S (en) Packaging
MX2014001920A (es) Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma.
WO2013095994A3 (en) Transparent aqueous fragrance microemulsions
CA141192S (en) Packaging
CA141190S (en) Packaging
AU2012101533A4 (en) The Wheelie Fast
HK1189602A (en) Anticancer fusion protein
AU2011905145A0 (en) Fusion Protein
GB201205549D0 (en) Electrochromism bulb: Theory, Technology & application
CA145333S (en) Flashlight
AU338253S (en) Retail Unloader
AU2011904559A0 (en) Ctshws500/2.7
AU2011904403A0 (en) The Ducks foot
EM19340840002S (es) Sillones
EM19340840001S (es) Sillones
EM13037470009S (es) Sillones